Terns Pharmaceuticals, Inc. (TERN) Discusses Efficacy and Safety Data Update for TERN-701 in Chronic Myeloid Leukemia Transcript

Core Viewpoint - Terns Pharmaceuticals is presenting data on TERN-701, an investigational oral allosteric BCR-ABL inhibitor for chronic myeloid leukemia (CML), highlighting its unprecedented efficacy and safety data, and potential best-in-disease profile [2]. Company Overview - Terns Pharmaceuticals is focused on developing TERN-701 for the treatment of CML, with plans to discuss key benchmarks and next steps for the drug's pivotal trial readiness [2]. Data Presentation - The company will provide a comprehensive view of the data supporting TERN-701's efficacy and safety, including details from Dr. Jabbour's ASH presentation [3].